Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status-Reference-Cited by-同舟云学术

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status

Published:2018 Issue: Volume:14 Page:7-12
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Hjortkjær Mette,Kanstrup Hanne,Jakobsen Anders,Steffensen Karina Dahl

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer;Colombo;Crit. Rev. Oncol. Hematol.,2014

2. Review role of topotecan in gynaecological cancers: current indications and perspectives;Lorusso;Crit. Rev. Oncol./Hematol.,2010

3. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer;Gordon;Gynecol. Oncol.,2004

4. Update on the treatment of recurrent ovarian cancer;Herzog;Women's Health,2006

5. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial;Poveda;J. Clin. Oncol.,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective;International Journal of Molecular Sciences;2023-07-25

2. Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma;Communications Medicine;2022-07-02

3. Veliparib for the treatment of solid malignancies;Journal of Oncology Pharmacy Practice;2022-01-17

4. Perspectives on PARP Inhibitor Combinations for Ovarian Cancer;Frontiers in Oncology;2021-12-15

5. The evolving role of PARP inhibitors in advanced ovarian cancer;Forum of Clinical Oncology;2021-05-01